FDA approves Crestor for artery disease prevention

TriMed Staff | | Health Imaging | Screening
  
Crestor, or rosuvastatin, in 3D.
Source: www.wdv.com/CellWorld		 
  
The FDA has approved AstraZeneca’s Crestor (rosuvastatin calcium) to treat hardening of the arteries, a precursor to the progression of plaque buildup in patients with elevated cholesterol.

The pharmaceutical company said that the FDA’s decision was based largely on the results of Measuring Effects on intima-media Thickness: an Evaluation Of Rosuvastatin (METEOR) study. The trial measured the effects of Crestor on plaque build-up in the arteries using carotid intima-media thickness and demonstrated a slowing of progression of atherosclerosis in patients with early signs of the atherosclerosis, elevated LDL cholesterol, and low cardiovascular risk.

The approval means that the drug, which currently has sales of approximately $2 billion (£958 million) annually, can be marketed more widely.

Last week, the London-based AstraZeneca revealed that Cobalt Pharmaceuticals, a Mississauga, Ontario-based generic drug maker, has filed with the FDA to sell cheaper copies of Crestor. AstraZeneca said it would challenge Cobalt’s generic application.

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.